VIMTALABSNSEVimta Labs Limited· PharmaceuticalsLowNeutral
Announced Thu, 15 May · 17:08 IST

Vimta Labs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on Jun 06, 2025

Board & Shareholder Meetings View source PDF

VIMTALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Vimta Labs has informed the exchanges that its 35th AGM will be held on Friday, June 6, 2025 at 10:00 AM via video conferencing, with a record date of May 30, 2025. Shareholders will vote on adopting FY25 audited financials, declaring a ₹2 per share dividend, and a 1:1 bonus share issue (one bonus share for every one held). Other items include raising the borrowing limit to ₹300 crores, expanding into the Biologics Contract Research & Development (CDMO) segment with a planned investment of about ₹50 crores, appointing M/s D Hanumanta Raju & Co as Secretarial Auditor for five years, re-appointing Dr. Yadagiri R Pendri as Independent Director for a second five-year term, and revising remuneration for three executive directors including Managing Director Ms. Harita Vasireddi. Remote e-voting runs from June 3 (9:00 AM) to June 5 (5:00 PM).

Likely market impact

If approved, the 1:1 bonus issue and ₹2 dividend are likely to be viewed positively by retail investors, effectively rewarding shareholders while expanding the share base. The proposed ₹300 crore borrowing limit and entry into the Biologics CDMO business signal growth ambitions but introduce higher debt capacity and execution risk that investors should weigh.